ImmunityBio [IBRX] vs Corcept Therapeutics [CORT] Detailed Stock Comparison
ImmunityBio
NASDAQ
Loading...
Corcept Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: ImmunityBio wins in 8 metrics, Corcept Therapeutics wins in 10 metrics, with 0 ties. Corcept Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | ImmunityBio | Corcept Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.31 | 78.71 | ImmunityBio |
| Price-to-Book Ratio | -3.96 | 14.60 | ImmunityBio |
| Debt-to-Equity Ratio | -1.48 | 1.04 | ImmunityBio |
| PEG Ratio | 0.09 | -26.76 | Corcept Therapeutics |
| EV/EBITDA | -11.49 | 87.24 | ImmunityBio |
| Profit Margin (TTM) | 100.00% | 18.67% | ImmunityBio |
| Operating Margin (TTM) | -269.76% | 13.72% | Corcept Therapeutics |
| EBITDA Margin (TTM) | N/A | 13.72% | N/A |
| Return on Equity | 84.72% | 21.70% | ImmunityBio |
| Return on Assets (TTM) | -42.14% | 8.36% | Corcept Therapeutics |
| Free Cash Flow (TTM) | $-398.12M | $195.90M | Corcept Therapeutics |
| 1-Year Return | -25.95% | 94.03% | Corcept Therapeutics |
| Price-to-Sales Ratio (TTM) | 42.42 | 12.97 | Corcept Therapeutics |
| Enterprise Value | $3.09B | $8.95B | Corcept Therapeutics |
| EV/Revenue Ratio | 54.61 | 12.50 | Corcept Therapeutics |
| Gross Profit Margin (TTM) | 99.49% | 98.23% | ImmunityBio |
| Revenue per Share (TTM) | $0 | $7 | Corcept Therapeutics |
| Earnings per Share (Diluted) | $-0.48 | $1.12 | Corcept Therapeutics |
| Beta (Stock Volatility) | -0.06 | 0.46 | ImmunityBio |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
ImmunityBio vs Corcept Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ImmunityBio | -0.39% | 0.00% | 7.17% | -6.62% | -14.48% | -1.17% |
| Corcept Therapeutics | 1.93% | 5.10% | 23.56% | 21.97% | 11.06% | 76.41% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ImmunityBio | -25.95% | -50.39% | -70.94% | -80.60% | -91.70% | -91.70% |
| Corcept Therapeutics | 94.03% | 232.89% | 380.38% | 2,256.95% | 2,195.57% | 1,655.98% |
News Based Sentiment: ImmunityBio vs Corcept Therapeutics
ImmunityBio
News based Sentiment: MIXED
October brought a mix of positive and negative developments for ImmunityBio, including regulatory approvals, promising clinical trial data, a significant financing round, but also a setback with an sBLA filing and a high valuation. These events collectively represent a significant month for the company and its investors.
Corcept Therapeutics
News based Sentiment: MIXED
Corcept experienced a month of conflicting signals, with strong sales of Korlym countered by lowered revenue guidance and a projected earnings decline. The upcoming FDA decisions on relacorilant are critical catalysts, but the recent insider selling and mixed analyst ratings add complexity to the investment picture.
Performance & Financial Health Analysis: ImmunityBio vs Corcept Therapeutics
| Metric | IBRX | CORT |
|---|---|---|
| Market Information | ||
| Market Cap | $2.49B | $9.29B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 8,037,890 | 733,300 |
| 90 Day Avg. Volume | 9,879,247 | 831,183 |
| Last Close | $2.53 | $89.85 |
| 52 Week Range | $1.83 - $7.48 | $42.01 - $117.33 |
| % from 52W High | -66.18% | -23.42% |
| All-Time High | $45.42 (Feb 22, 2021) | $117.33 (Mar 31, 2025) |
| % from All-Time High | -94.43% | -23.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 24.24% | 0.19% |
| Quarterly Earnings Growth | 24.24% | -0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.19% |
| Operating Margin (TTM) | -2.70% | 0.14% |
| Return on Equity (TTM) | 0.85% | 0.22% |
| Debt to Equity (MRQ) | -1.48 | 1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.62 | $6.04 |
| Cash per Share (MRQ) | $0.16 | $3.25 |
| Operating Cash Flow (TTM) | $-349,558,016 | $182.19M |
| Levered Free Cash Flow (TTM) | $-249,235,872 | $166.88M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: ImmunityBio vs Corcept Therapeutics
| Metric | IBRX | CORT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.31 | 78.71 |
| Forward P/E | -4.03 | 50.37 |
| PEG Ratio | 0.09 | -26.76 |
| Price to Sales (TTM) | 42.42 | 12.97 |
| Price to Book (MRQ) | -3.96 | 14.60 |
| Market Capitalization | ||
| Market Capitalization | $2.49B | $9.29B |
| Enterprise Value | $3.09B | $8.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 54.61 | 12.50 |
| Enterprise to EBITDA | -11.49 | 87.24 |
| Risk & Other Metrics | ||
| Beta | -0.06 | 0.46 |
| Book Value per Share (MRQ) | $-0.62 | $6.04 |
Financial Statements Comparison: ImmunityBio vs Corcept Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IBRX | CORT |
|---|---|---|
| Revenue/Sales | $16.52M | $157.21M |
| Cost of Goods Sold | $58,000 | $2.40M |
| Gross Profit | $16.46M | $154.81M |
| Research & Development | $48.23M | $60.74M |
| Operating Income (EBIT) | $-64.43M | $3.42M |
| EBITDA | $-102.70M | $3.88M |
| Pre-Tax Income | $-129.90M | $9.62M |
| Income Tax | $-234,000 | $-10.93M |
| Net Income (Profit) | $-129.67M | $20.55M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IBRX | CORT |
|---|---|---|
| Cash & Equivalents | $60.66M | $89.82M |
| Total Current Assets | $109.16M | $438.50M |
| Total Current Liabilities | $49.21M | $143.07M |
| Long-Term Debt | $518.81M | $5.85M |
| Total Shareholders Equity | $-590.48M | $683.29M |
| Retained Earnings | $-3.50B | $564.28M |
| Property, Plant & Equipment | $106.70M | $7.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IBRX | CORT |
|---|---|---|
| Operating Cash Flow | $-35.91M | $34.72M |
| Capital Expenditures | $-1.08M | $-104,000 |
| Free Cash Flow | $-80.83M | $5.02M |
| Debt Repayment | $-4,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IBRX | CORT |
|---|---|---|
| Shares Short | 84.56M | 10.81M |
| Short Ratio | 8.53 | 16.33 |
| Short % of Float | 0.29% | 0.14% |
| Average Daily Volume (10 Day) | 8,037,890 | 733,300 |
| Average Daily Volume (90 Day) | 9,879,247 | 831,183 |
| Shares Outstanding | 852.90M | 105.11M |
| Float Shares | 193.56M | 86.95M |
| % Held by Insiders | 0.69% | 0.12% |
| % Held by Institutions | 0.13% | 0.76% |
Dividend Analysis & Yield Comparison: ImmunityBio vs Corcept Therapeutics
| Metric | IBRX | CORT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |